• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mallinckrodt mulls sale of generics biz

May 31, 2017 By Sarah Faulkner

Mallinckrodt PharmaceuticalsMallinckrodt Pharmaceuticals (NYSE:MNK) is reportedly considering a sale of its generic drug unit in an effort to focus its portfolio on high-margin branded drugs, according to a report from Reuters.

The divestment comes only months after the company sold its nuclear imaging business to IBA Molecular for $690 million. The sale of its generics business could bring in as much as $2 billion to the pharmaceutical company.

Mallinckrodt has hired investment back Credit Suisse Group to run the sales process, but there is no guarantee that any talk of a transaction will result in a deal.

The company’s generics unit saw sales decline 18% between 2015 and 2016, while sales of branded specialty drugs jumped nearly 40% to $2.3 billion during the same period.

“We expect continued pressure on the segment from competitive entrants and market pricing in coming quarters,” chief financial officer Matthew Harbaugh said of its generics unit during an earnings call.

The move towards branded drugs is a pivot from the company’s original intent – when Mallinckrodt was spun out of Covidien in 2013, generics and nuclear imaging products represented 90% of its revenue.

But over time, Mallinckrodt has invested in several acquisitions for its specialty pharmaceutical unit, including the $5.6 billion purchase of Questcor Pharmaceuticals in 2014. This deal bought the company its pricey anti-inflammatory drug, H.P. Acthar.

The $34,000 product now accounts for about 1/3 of Mallinckrodt’s revenue.

Material from Reuters was used in this report.

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Covidien, Mallinckrodt Pharmaceuticals

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS